NASDAQ:SNTS Santarus (SNTS) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free SNTS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range$16,995.00▼$16,995.0052-Week Range N/AVolume54,432 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Santarus alerts: Email Address Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About Santarus Stock (NASDAQ:SNTS)Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company’s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company’s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report SNTS Stock News HeadlinesFebruary 23, 2024 | morningstar.comSociete Nationale des Telecommunications SONATEL SNTSDecember 30, 2023 | mirror.co.ukAnt McPartlin and wife Anne-Marie beam as they jet off to Dubai for plush New Year holidayApril 25, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.December 18, 2023 | bbc.comJack Ma's Ant Group: World's biggest market debut suspendedOctober 12, 2023 | thestreet.comBiotech Stock Mailbag: Cardium TherapeuticsJuly 27, 2023 | investing.comSociete Nationale des Telecommunications du Senegal (SNTS)May 25, 2023 | wsj.comSociete Nationale de Telecommunications du SenegalFebruary 17, 2023 | duluthnewstribune.comSaints report: Bostedt, CSS win their sixth straight in men’s hockeyApril 25, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 14, 2023 | duluthnewstribune.comSaints report: CSS earn MIAC men’s hockey sweep of CobbersFebruary 14, 2023 | duluthnewstribune.comSaints report: CSS men victorious at AugsburgDecember 26, 2022 | thestreet.comSantarus Stock Hits New 52-Week High (SNTS)September 20, 2022 | usatoday.comTampa Bay Buccaneers at New Orleans Saints: Predictions, picks and odds for NFL Week 2 matchupAugust 22, 2022 | thestreet.comCramer's 'Mad Money' Recap: The Knot Worth TyingAugust 22, 2022 | thestreet.com5 Stocks Insiders are Buying This WeekSee More Headlines Receive SNTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santarus and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNTS CUSIP80281730 CIK1172480 Webwww.santarus.com Phone+1-858-3145700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report SNTS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Santarus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Santarus investors own include Baidu (BIDU), Home Depot (HD), Pharmacyclics (PCYC), Yelp (YELP), ACADIA Pharmaceuticals (Acad), Altaba (AABA), Allergan (AGN), Alexion Pharmaceuticals (ALXN) and Cree (CREE). This page (NASDAQ:SNTS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santarus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
